Samples were taken from the BM of 39 MM patients treated with bortezomib-based regimens and the expression of the POMP, PSMB5, NRF2, XBP1, cMAF and MAFB proteins was determined using enzyme-linked immunosorbent assay (ELISA). Here, POMP is linked to Miyoshi myopathy.